drugset / Trial / NCT07224035
Helicobacter Pylori Screening and Treatment in the At-risk South Florida Community- AIM 1
Phase 4
Completed
430 enrolled
University of Miami
NRG Oncology · collabPhathom Pharmaceuticals, Inc. · collab
NaSingle-groupOpen-labelScreening
Summary
H. pylori is an infection of the stomach that can cause chronic gastritis, gastric cancer and peptic ulcer disease. The goal of this study is to screen people for this infection and offer treatment for those who test positive for the infection. By treating those who are positive for H. pylori, there is an opportunity to prevent gastritis, peptic ulcer disease, and even gastric cancer.
Timeline
- Start
- 2022-10-15
- Primary completion
- 2026-02-09
- Completion
- 2026-02-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Amoxicillin | Other / unclassified | 500 mg | — |
| Subject | Clarithromycin | Small molecule | 500 mg | — |
| Subject | Vonoprazan | Other / unclassified | 20 mg | — |